Search results for "Schedule"

showing 10 items of 567 documents

FDG-PET mapping the brain substrates of visuo-constructive processing in Alzheimer´s disease

2010

The anatomical basis of visuo-constructive impairment in AD is widely unexplored. FDG-PET can be used to determine functional neuronal networks underlying specific cognitive performance in the human brain. In the present study, we determined the pattern of cortical metabolism that was associated with visuo-constructive performance in AD. We employed two widely used visuo-constructive tests that differ in their demand on visual perception and processing capacity. Resting state FDG-PET scans were obtained in 29 probable AD patients, and cognitive tests were administered. We made a voxel-based regression analysis of FDG uptake to scores in visual test performance, using the SPM5 software. Perf…

MaleVisual perceptiongenetic structuresPrecuneusNeuropsychological TestsBrain mappingVisual processingFolic AcidAlzheimer DiseaseFluorodeoxyglucose F18medicineHumansBiological PsychiatryAgedAged 80 and overBrain MappingVisual testCognitive neuroscience of visual object recognitionBrainLimbic lobeHuman brainMiddle AgedVitamin B 12Psychiatry and Mental healthmedicine.anatomical_structurenervous systemPositron-Emission TomographyLinear ModelsVisual PerceptionFemaleMental Status SchedulePsychologyNeurosciencePhotic StimulationJournal of Psychiatric Research
researchProduct

Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study

2017

Objectives: Osteonecrosis of the jaw (ONJ) is a potentially severe adverse effect of bisphosphonates (BP). Although the risk of ONJ increases with increasing duration of BP treatment, there are currently no reliable estimates of the ONJ time to onset (TTO). The objective of this study was to estimate the TTO and associated risk factors in BP-treated patients. Subjects and Methods: Retrospective analysis of data from 22 secondary care centres in seven countries relevant to 349 patients who developed BP-related ONJ between 2004 and 2012. Results: The median (95%CI) TTO was 6.0 years in patients treated with alendronate (n = 88) and 2.2 years in those treated with zoledronate (n = 218). Multiv…

MalebisphosphonateTime Factorsmedicine.medical_treatmentOsteoporosis0302 clinical medicineRisk Factors80 and overosteoporosijaw osteonecrosiAged 80 and overBone Density Conservation AgentsDiphosphonatesjaw osteonecrosisjaw osteonecrosis bisphosphonates breast cancer multiple myeloma prostate cance osteoporosisIncidenceIncidence (epidemiology)Otorhinolaryngology2734 Pathology and Forensic MedicineMiddle Agedprostate cancermultiple myeloma030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleAdultmedicine.medical_specialty2734Drug Administration SchedulePathology and Forensic Medicine03 medical and health sciencesbreast cancerbisphosphonates; breast cancer; jaw osteonecrosis; multiple myeloma; osteoporosis; prostate cancer; Adult; Aged; Aged 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cross-Sectional Studies; Diphosphonates; Drug Administration Schedule; Female; Humans; Incidence; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Otorhinolaryngology; 2734; Pathology and Forensic Medicine; Dentistry (all)Internal medicinemedicineHumansBisphosphonates; Breast cancer; Jaw osteonecrosis; Multiple myeloma; Osteoporosis; Prostate cancer; Otorhinolaryngology2734 Pathology and Forensic Medicine; Dentistry (all)prostate canceAdverse effectGeneral DentistrybisphosphonatesAgedProportional Hazards ModelsRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawbusiness.industryProportional hazards modelRetrospective cohort study030206 dentistryBisphosphonatemedicine.diseaseosteoporosisSurgeryCross-Sectional StudiesOtorhinolaryngologyMultivariate AnalysisDentistry (all)businessOsteonecrosis of the jaw
researchProduct

Effect of mesalazine on epithelial cell proliferation in colonic diverticular disease

2007

Background and aims: increased epithelial cell proliferation may be detected in diverticular disease, but antibiotics have failed in reducing it. We assess therefore the effect of mesalazine on epithelial cell proliferation in diverticular disease. Methods: a prospective study was conducted on 20 consecutive patients with a new endoscopic diagnosis of symptomatic uncomplicated diverticular disease. The patients were treated with mesalazine 1.6 mg/day for 1 year. The Ki-67 antigen index of the whole crypt and in the upper third was separately evaluated before and after starting the treatment. Results: cell proliferation index was higher in diverticular disease patients than healthy controls …

Malediverticular diseaseSeverity of Illness IndexGastroenterologychemistry.chemical_compoundReference ValuesProspective StudiesIntestinal MucosaMesalamineProspective cohort studyCell proliferationtreatmentmedicine.diagnostic_testAnti-Inflammatory Agents Non-SteroidalBiopsy Needledigestive oral and skin physiologyGastroenterologyColonoscopyMiddle AgedImmunohistochemistryDiverticulosisDose–response relationshipTreatment OutcomemesalazineDiverticular diseaseFemalemedicine.medical_specialtyCryptRisk Assessmentdigestive systemDrug Administration ScheduleStatistics NonparametricMesalazineInternal medicineBiopsyDiverticulosis ColonicmedicineHumansAgedProbabilityDose-Response Relationship DrugHepatologybusiness.industryCase-control studyEpithelial Cellsmedicine.diseasedigestive system diseasescolonic mucosaKi-67 AntigenchemistryCase-Control StudiesbusinessFollow-Up StudiesDigestive and Liver Disease
researchProduct

Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multi…

2020

Abstract Aims To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban. Methods and results We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities. Up to two nights of hospital stay were permitted. Rivaroxaban was given at the approved dose for PE for ≥3 months. The primary outcome was sympto…

Malehome treatmentpulmonary embolismrisk stratification030204 cardiovascular system & hematology0302 clinical medicineRivaroxabanRecurrenceRisk FactorsOutpatientsMedicineProspective StudiesRight ventricular dysfunctionEarly dischargeAged 80 and overeducation.field_of_studyHome treatmentriskinarviointiMiddle AgedEUROPEAN-SOCIETYPatient DischargeINPATIENT TREATMENT3. Good healthPulmonary embolismTreatment OutcomeHOSPITALIZATIONAmbulatoryright ventricular dysfunctionFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyAdolescentmanagement trialpotilaan kotiuttaminenkotihoitoPopulationDrug Administration Schedule03 medical and health sciencesYoung AdultInternal medicineMANAGEMENTkliiniset kokeetHumansseurantaddc:610Home treatment; Management trial; Pulmonary embolism; Right ventricular dysfunction; Risk stratification; RivaroxabaneducationRisk stratificationAgedRivaroxabanbusiness.industryManagement trial030229 sport sciences3126 Surgery anesthesiology intensive care radiologymedicine.diseaseInterim analysisOUTPATIENT TREATMENTConfidence intervalhyytymisenestohoitoClinical trialTHROMBOSIS3121 General medicine internal medicine and other clinical medicinelääkehoitosydän- ja verisuonitauditveritulppabusinessPulmonary EmbolismFactor Xa InhibitorsEuropean heart journal
researchProduct

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated p…

2011

Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®) hexa/Infanrix(®)-IPV+Hib (diphtheria, tetanus, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b). After the 3-dose infant series, immunogenic noninferiority was demonstrated for all concomitantly administered antigens between the PCV13 and PCV7 groups. All antigens elicited good booster responses after the toddler dose except pertussis toxoid; however, 99.6% subjects achieved pertussis toxoid protective antibody level ≥5EU/mL in both groups. These results support the …

Malemedicine.disease_causeAntibodies ViralDiphtheria-Tetanus-acellular Pertussis Vaccinescomplex mixturesPneumococcal conjugate vaccineDrug Administration SchedulePneumococcal VaccinesAntigenDouble-Blind MethodGermanymedicineHumansHepatitis B VaccinesVaccines CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesVaccines ConjugateGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaPoliovirusImmunogenicityPublic Health Environmental and Occupational HealthInfantHepatitis Bmedicine.diseaseVirologyAntibodies BacterialPoliovirus Vaccine InactivatedInfectious DiseasesTreatment OutcomeSpainbiology.proteinMolecular MedicineFemaleAntibodybusinessmedicine.drugVaccine
researchProduct

Influence of Stress in the Onset of Eating Disorders: Data From a Two-Stage Epidemiologic Controlled Study

2006

Background We explore the role of stress in the onset of eating disorders (EDs) in a community sample of adolescents, the mediating role of psychiatric comorbidity and the quantitative evolution of stress in the year preceding the onset of an ED. Methods The Life Events and Difficulties Schedule interview was applied to a sample with 32 cases and 32 controls selected from a two-phase epidemiologic study among a representative population of adolescents, followed by a decay model to assess acute and chronic stress in the year preceding the onset of ED. Psychiatric comorbidity was assessed using the SCAN interview. Results Cases (46.9%) and 9.4% of controls were found to have associated psychi…

Malemedicine.medical_specialtyAdolescentPersonality InventoryPopulationComorbiditySampling StudiesFeeding and Eating DisordersLife Change Eventssymbols.namesakeSurveys and QuestionnairesInternal medicineHumansMedicineChronic stressChildPsychiatryeducationApplied PsychologyFisher's exact testPsychiatric Status Rating Scaleseducation.field_of_studybusiness.industryData CollectionMental DisordersLife Events and Difficulties ScheduleCase-control studymedicine.diseaseComorbidityPsychiatry and Mental healthEating disordersSpainAnorexia nervosa (differential diagnoses)Case-Control StudiesChronic DiseasesymbolsFemalebusinessStress PsychologicalPsychosomatic Medicine
researchProduct

Antibiotic single-dose prophylaxis of shunt infections.

1989

Shunt infections after implantation or revision of a shunt for CSF drainage in hydrocephalic patients are serious complications. In view of their frequency, this study investigated the efficacy of prophylactic administration of a single dose of the antibiotic cefazedone in reducing in the post-operative infection rate. Fifty children of up to 14 years of age suffering from hydrocephalus of various etiologies were treated prophylactically and compared with a similar untreated group. The diagnosis of infection was based mainly on microbiological and clinical observations and investigations. Classical infection parameters were also recorded and evaluated, but played only a secondary role in es…

Malemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentAntibioticsInfectionsDrug Administration ScheduleCefazedoneCefazolinmedicineHumansDerivationProspective StudiesChildChemotherapyInfection Controlbusiness.industryInfant NewbornInfantDrug Resistance MicrobialGeneral Medicinemedicine.diseaseCerebrospinal Fluid ShuntsHydrocephalusShunt (medical)SurgeryAnti-Bacterial AgentsAnesthesiaChild PreschoolSurgeryFemaleNeurology (clinical)NeurosurgeryComplicationbusinessmedicine.drugNeurosurgical review
researchProduct

Risk factors for postoperative delirium after colorectal surgery for carcinoma

2011

Background and aim: Data regarding the incidence and risk factors for postoperative delirium (PD) after gastrointestinal surgery are heterogeneous because they include both benign and malignant disease. The aim of this study was to investigate the incidence and risk factors for PD in 100 consecutive patients over 65 years who underwent colorectal surgery for carcinoma. Methods: Pre-operative cognitive function was assessed using the Mini Mental State Examination. The onset of PD was diagnosed by the Confusion Assessment Methods administered to the patients every 12 h starting from the first postoperative day to discharge. The severity of PD was also evaluated with the Delirium Rating Scale.…

Malemedicine.medical_specialtyAlcohol abuseColorectal NeoplasmAcute confusionPostoperative ComplicationsElderlyRisk FactorsColorectal surgeryInternal medicinemedicineCarcinomaHumansProspective StudiesProspective cohort studyCancerAgedUnivariate analysisMini–Mental State Examinationmedicine.diagnostic_testbusiness.industryOncology (nursing)IncidenceRisk Factorpostoperative delirium Colorectal surgery Elderly Acute confusion CancerCarcinomaPostoperative deliriumDeliriumpostoperative delirium colorectal surgeryGeneral Medicinemedicine.diseaseColorectal surgeryProspective StudieSettore MED/18 - Chirurgia GeneraleAnesthesiaDeliriumFemalePostoperative Complicationmedicine.symptomColorectal NeoplasmsbusinessComplicationMental Status ScheduleHuman
researchProduct

Evaluation of an alternative dosing regimenwith tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy.

2007

AIM: To examine the preference for two dosing regimens of 20 mg of tadalafil, on demand or three times per week, in men affected with erectile dysfunction (ED) in Italy. METHODS: Scheduled Use versus on demand Regimen Evaluation (SURE) is a multicenter, crossover and open-label study, involving 94 urology centers in Italy. Patients aged 18 years or older affected with ED for at least 3 months were enrolled and randomized to 20 mg of tadalafil treatment on demand or three times per week for 5-6 weeks. After a 1-week washout, patients were crossed over to the alternate regimen for 5-6 weeks. A treatment preference question was used to determine the preferred treatment regimen. International I…

Malemedicine.medical_specialtyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcome; Nephrology; EndocrinologyPhosphodiesterase Inhibitorserectile dysfunctionUrologyerectile dysfunction; SURE study; on demand; three times per week; alternate; tadalafilon demandDrug Administration Schedulelaw.inventionSettore MED/24 - UrologiaEndocrinologyRandomized controlled triallawOn demandInternal medicinealternateMedicineHumansClinical significanceDosingthree times per weekErectile dysfunction SURE Study on demand three times per week alternate tadalafilSURE studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTadalafilSurgeryRegimenErectile dysfunctionTreatment OutcomeItalyNephrologyAlternate; Erectile dysfunction; On demand; SURE study; Tadalafil; Three times per week; Carbolines; Cross-Over Studies; Drug Administration Schedule; Erectile Dysfunction; Humans; Italy; Male; Middle Aged; Phosphodiesterase Inhibitors; Tadalafil; Treatment Outcomebusinesstadalafilmedicine.drugCarbolines
researchProduct

Phase II dose escalation study of caspofungin for invasive Aspergillosis.

2011

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥4 in 2 of 8 patients or ≥3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics w…

Malemedicine.medical_specialtyAntifungal AgentsDoseBiologyPharmacologyClinical TherapeuticsAspergillosisGastroenterologyDrug Administration ScheduleCohort Studieschemistry.chemical_compoundEchinocandinsLipopeptidesPharmacokineticsCaspofunginInternal medicinemedicineAspergillosisHumansPharmacology (medical)PharmacologyVoriconazoleVolume of distributionDose-Response Relationship DrugLiterMiddle Agedmedicine.diseaseSurvival AnalysisInfectious DiseasesTreatment OutcomechemistryToxicityFemaleCaspofunginmedicine.drugFollow-Up StudiesAntimicrobial agents and chemotherapy
researchProduct